Bajaj Healthcare Limited has informed the Exchange regarding a press release dated May 08, 2026, titled "Press Release for the quarter and financial year ended 31st March 2026 ".
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bajaj Healthcare reported FY26 revenue of Rs 6,110.3 Mn, up 12.6% YoY, driven by strong API exports (+51.6% to Rs 1,881.4 Mn) and formulations growth (+12.6% to Rs 1,033.2 Mn), though domestic API sales declined 2.2%. PAT from continuing operations grew 27.1% to Rs 545.6 Mn with margins improving to 8.8% from 7.9%. However, EBITDA margin compressed to 18.3% from 18.8% due to price erosion in domestic APIs and elevated raw material costs from geopolitical disruptions. The company reversed previously recognised income from a technical know-how transfer to a Middle East party due to regional instability. Q4 standalone revenue was flat at Rs 1,530.6 Mn. The company also converted 2,079,409 warrants into equity, bringing Rs 527 Mn in additional capital.
Strong profitability growth (27% PAT increase) despite margin pressure shows operational efficiency, while the export-led growth strategy is working. The exceptional item from the cancelled Middle East arrangement is a one-time charge but highlights geopolitical risk exposure. Overall, the results are positive for shareholders with improving margins and export momentum.